Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, MJ. Hochmair, M. Özgüroğlu, JH. Ji, MC. Garassino, O. Voitko, A. Poltoratskiy, E. Musso, L. Havel, I. Bondarenko, G. Losonczy, N. Conev, H. Mann, TB. Dalvi, H. Jiang, JW. Goldman

. 2022 ; 7 (2) : 100408. [pub] 20220310

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018947

BACKGROUND: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus tremelimumab plus EP numerically improved OS versus EP, but did not reach statistical significance. Here we report updated OS in censored patients after median follow-up of >3 years. PATIENTS AND METHODS: 805 patients with treatment-naïve ES-SCLC were randomized 1 : 1 : 1 to durvalumab plus EP, durvalumab plus tremelimumab plus EP, or EP. The two primary endpoints were OS for durvalumab plus EP versus EP and for durvalumab plus tremelimumab plus EP versus EP. RESULTS: As of 22 March 2021 (median follow-up 39.4 months, 86% maturity), durvalumab plus EP continued to demonstrate improved OS versus EP: hazard ratio (HR) 0.71 [95% confidence interval (CI) 0.60-0.86; nominal P = 0.0003]; median OS was 12.9 versus 10.5 months, and 36-month OS rate was 17.6% versus 5.8%. Durvalumab plus tremelimumab plus EP continued to numerically improve OS versus EP: HR 0.81 (95% CI: 0.67-0.97; nominal P = 0.0200); median OS was 10.4 months, and 36-month OS rate was 15.3%. Twenty-seven and nineteen patients in the durvalumab plus EP and durvalumab plus tremelimumab plus EP arms, respectively, remained on durvalumab treatment at data cut-off. CONCLUSIONS: Three times more patients were estimated to be alive at 3 years when treated with durvalumab plus EP versus EP, with the majority still receiving durvalumab at data cut-off, further establishing durvalumab plus EP as first-line standard of care for ES-SCLC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018947
003      
CZ-PrNML
005      
20240507094556.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.esmoop.2022.100408 $2 doi
035    __
$a (PubMed)35279527
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Paz-Ares, L $u Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic address: lpazaresr@seom.org
245    10
$a Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN / $c L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, MJ. Hochmair, M. Özgüroğlu, JH. Ji, MC. Garassino, O. Voitko, A. Poltoratskiy, E. Musso, L. Havel, I. Bondarenko, G. Losonczy, N. Conev, H. Mann, TB. Dalvi, H. Jiang, JW. Goldman
520    9_
$a BACKGROUND: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus tremelimumab plus EP numerically improved OS versus EP, but did not reach statistical significance. Here we report updated OS in censored patients after median follow-up of >3 years. PATIENTS AND METHODS: 805 patients with treatment-naïve ES-SCLC were randomized 1 : 1 : 1 to durvalumab plus EP, durvalumab plus tremelimumab plus EP, or EP. The two primary endpoints were OS for durvalumab plus EP versus EP and for durvalumab plus tremelimumab plus EP versus EP. RESULTS: As of 22 March 2021 (median follow-up 39.4 months, 86% maturity), durvalumab plus EP continued to demonstrate improved OS versus EP: hazard ratio (HR) 0.71 [95% confidence interval (CI) 0.60-0.86; nominal P = 0.0003]; median OS was 12.9 versus 10.5 months, and 36-month OS rate was 17.6% versus 5.8%. Durvalumab plus tremelimumab plus EP continued to numerically improve OS versus EP: HR 0.81 (95% CI: 0.67-0.97; nominal P = 0.0200); median OS was 10.4 months, and 36-month OS rate was 15.3%. Twenty-seven and nineteen patients in the durvalumab plus EP and durvalumab plus tremelimumab plus EP arms, respectively, remained on durvalumab treatment at data cut-off. CONCLUSIONS: Three times more patients were estimated to be alive at 3 years when treated with durvalumab plus EP versus EP, with the majority still receiving durvalumab at data cut-off, further establishing durvalumab plus EP as first-line standard of care for ES-SCLC.
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a etoposid $x terapeutické užití $7 D005047
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x farmakoterapie $7 D008175
650    _2
$a platina $x terapeutické užití $7 D010984
650    12
$a malobuněčný karcinom plic $x farmakoterapie $7 D055752
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chen, Y $u Cancer & Hematology Centers of Western Michigan, Grand Rapids, USA
700    1_
$a Reinmuth, N $u Asklepios Lung Clinic, Munich-Gauting, Germany
700    1_
$a Hotta, K $u Okayama University Hospital, Okayama, Japan
700    1_
$a Trukhin, D $u Odessa Regional Oncological Dispensary, Odessa, Ukraine
700    1_
$a Statsenko, G $u Omsk Regional Cancer Center, Omsk, Russian Federation
700    1_
$a Hochmair, M J $u Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Krankenhaus Nord, Vienna, Austria
700    1_
$a Özgüroğlu, M $u Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
700    1_
$a Ji, J H $u Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea
700    1_
$a Garassino, Marina $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; The University of Chicago Department of Medicine, Section of Hematology/Oncology, Chicago, USA $7 xx0280337
700    1_
$a Voitko, O $u Kyiv City Clinical Oncological Centre, Kyiv, Ukraine
700    1_
$a Poltoratskiy, A $u Petrov Research Institute of Oncology, St Petersburg, Russian Federation
700    1_
$a Musso, E $u AO Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy
700    1_
$a Havel, Libor, $u Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1967-2023 $7 xx0065540
700    1_
$a Bondarenko, I $u Dnipropetrovsk Medical Academy, Dnipro, Ukraine
700    1_
$a Losonczy, G $u Semmelweis University, Budapest, Hungary
700    1_
$a Conev, N $u Medical Oncology, UMHAT St Marina, Varna, Bulgaria
700    1_
$a Mann, H $u AstraZeneca, Cambridge, UK
700    1_
$a Dalvi, T B $u AstraZeneca, Gaithersburg USA
700    1_
$a Jiang, H $u AstraZeneca, Gaithersburg USA
700    1_
$a Goldman, J W $u David Geffen School of Medicine at UCLA, Los Angeles, USA
773    0_
$w MED00196632 $t ESMO open $x 2059-7029 $g Roč. 7, č. 2 (2022), s. 100408
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35279527 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20240507094553 $b ABA008
999    __
$a ok $b bmc $g 1822506 $s 1170190
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 7 $c 2 $d 100408 $e 20220310 $i 2059-7029 $m ESMO open $n ESMO Open $x MED00196632
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace